Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

In Brief

City of Hope expands clinical trial access across U.S. with new national model

City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds

When it comes to their survival, cancer cells have a host of backup plans.

September 19, 2025

Vol.51 No.34

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

YOU MAY BE INTERESTED IN

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

City of Hope expands clinical trial access across U.S. with new national model

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds

Renew today!

Subscriber content

Never miss an issue!

Login